Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily. The primary outcome was the first major vascular event (nonfatal myocardial infarction, death from coronary causes, stroke, or arterial revascularization). RESULTS: During a median follow-up period of 3.9 years, participants who were assigned to extended-release niacin-laropiprant had an LDL cholesterol level that was an average of 10 mg per deciliter (0.25 mmol per liter as measured in the central laboratory) lower and an HDL cholesterol level that was an average of 6 mg per deciliter (0.16 mmol per liter) higher than the levels in those assigned to placebo. Assignment to niacin-laropiprant, as compared with assignment to placebo, had no significant effect on the incidence of major vascular events (13.2% and 13.7% of participants with an event, respectively; rate ratio, 0.96; 95% confidence interval [CI], 0.90 to 1.03; P=0.29). Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious (absolute excess as compared with placebo, 3.7 percentage points; P<0.001) and with an increased incidence of diabetes diagnoses (absolute excess, 1.3 percentage points; P<0.001), as well as increases in serious adverse events associated with the gastrointestinal system (absolute excess, 1.0 percentage point; P<0.001), musculoskeletal system (absolute excess, 0.7 percentage points; P<0.001), skin (absolute excess, 0.3 percentage points; P=0.003), and unexpectedly, infection (absolute excess, 1.4 percentage points; P<0.001) and bleeding (absolute excess, 0.7 percentage points; P<0.001). CONCLUSIONS: Among participants with atherosclerotic vascular disease, the addition of extended-release niacin-laropiprant to statin-based LDL cholesterol-lowering therapy did not significantly reduce the risk of major vascular events but did increase the risk of serious adverse events. (Funded by Merck and others; HPS2-THRIVE ClinicalTrials.gov number, NCT00461630.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the EU, treatment with niacin was stopped after the AIM-HIGH and HPS2-THRIVE trials showed no improvement in MACE and an increased occurrence of undesirable side effects [123, 124].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [124]
In the citing paper
“Nonetheless, these studies also did not prospectively enroll patients with elevated TG levels despite statin therapy,6, 12, 13, 14, 15”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“Prior CV outcome studies that administered therapies with TG‐lowering effects (niacin or fenofibrate) on top of statin therapy did not reach their primary endpoints.”
From Rationale and design of REDUCE‐IT : Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (2017) · cites this paper as [14]
In the citing paper
“and an increased incidence of new-onset diabetes (absolute excess, 1.3 percentage points; P < 0.001) and disturbances in diabetes management among those with diabetes in the HPS2-THRIVE trial in those on combination therapy (161).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
In the citing paper
“Large clinical trials, including the Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) and Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trials, failed to demonstrate a benefit of adding niacin to individuals on appropriate statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [161]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Prostaglandins and Inflammation
Ricciotti, E., & FitzGerald, G. A. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.207449 · Cited by 3,803
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Clofibrate and Niacin in Coronary Heart Disease
(1975) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1975.03240160024021 · Cited by 1,747
Cited by
Items 601–700 of 1,676
Cardiovascular Risk Factors and Disease in Women
Gill, S. K. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.01.007 · Cited by 30
Should we welcome food industry funding of public health research?
Aveyard, P. N., Yach, D., Gilmore, A., & Capewell, S. (2016) · BMJ · doi:10.1136/bmj.i2161 · Cited by 26
Page, M. M., & Watts, G. F. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13070 · Cited by 28
Adiels, M., Chapman, M. J., Robillard, P., Krempf, M., Laville, M., & Borén, J. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.083 · Cited by 25
“Indeed, such a study would likely further our understanding of side effects specific to ER niacin as compared to those observed when niacin is used either on a background of statin therapy (as in AIM-HIGH), or a background of both a statin and laropiprant (as in HPS2-THRIVE).(18,19) Any comment on the relevance of our…”
BackgroundResultHigh-density lipoprotein cholesterol and causes of death in chronic kidney disease
Navaneethan, S. D., Schold, J. D., Walther, C. P., Arrigain, S., Jolly, S. E., Virani, S. S., Winkelmayer, W. C., & Nally, J. V. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.085 · Cited by 28
Prevention and management of statin adverse effects: A practical approach for pharmacists
Barry, A. R., Beach, J. E., & Pearson, G. J. (2018) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163518768534 · Cited by 30
Lv, G., Wang, G., Xia, Z., Wang, H.-X., Liu, N., Wei, W., Huang, Y., & Zhang, W. (2019) · Military Medical Research · doi:10.1186/s40779-019-0191-z · Cited by 27
Residual cardiovascular risk among people with diabetes
Dash, S., & Leiter, L. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13646 · Cited by 27
“In the HSP-2 THRIVE study, the effects of a combination of laropripant, a prostaglandin D2 inhibitor, with niacin were evaluated.(77) Patients with established vascular disease on statins were randomized to receive niacin/laropripant or placebo—32% of patients had diabetes.”
Managing dyslipidemia in patients with Type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912734 · Cited by 32
Lipoprotein(a) Testing Patterns in a Large Health System
Kelsey, M. D., Page, C. B., Alhanti, B., Rhodes, S. L., Kent, S. T., Peterson, E. D., & Pagidipati, N. J. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.05.018 · Cited by 24
New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk
Adhyaru, B. B., & Jacobson, T. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.001 · Cited by 28
Takahashi, D., Wada, H., Ogita, M., Yasuda, K., Nishio, R., Takeuchi, M., Shitara, J., Tsuboi, S., Dohi, T., Suwa, S., et al. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.12.014 · Cited by 27
Zhou, L., Liu, J., An, Y., Wang, Y., & Wang, G. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.898305 · Cited by 31
“Low HDL-C was one of the most important factors for the residual risk, but there is no effective HDLC-raising therapy till present (52).”
BackgroundHung, M., & Tsimikas, S. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000131 · Cited by 27
Kong, D., Li, J., Shen, Y., Liu, G., Zuo, S., Bo, T., Ji, Y. H., Lü, A., Lazarus, M., BREYER, R. M., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.238261 · Cited by 25
“, 2011) and HPS2-THRIVE (Group et al., 2014), an extended-release (ER) alternative failed to recapitulate the benefits of the established cardioprotective regimen of niacin, despite significant increases in HDLc and reduction of TG levels in patients.”
BackgroundInfluentialHaghikia, A., & Landmesser, U. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.12.013 · Cited by 28
Kidney disease trials for the 21st century: innovations in design and conduct
Herrington, W. G., Staplin, N., & Haynes, R. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0212-x · Cited by 27
Metabolic and cardiovascular outcomes of bariatric surgery
Iqbal, Z., Adam, S., Ho, J. H., Syed, A. A., Ammori, B. J., Malik, R. A., & Soran, H. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000696 · Cited by 28
Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs
KONES, R. J., & Rumana, U. (2015) · Drugs · doi:10.1007/s40265-015-0429-3 · Cited by 27
Venu, V. K. P., Adijiang, A., Seibert, T., Chen, Y., Shi, C., Batulan, Z., & O’Brien, E. R. (2017) · The FASEB Journal · doi:10.1096/fj.201601188r · Cited by 27
Current pharmacotherapeutic options for primary dyslipidemia in adults
Cicero, A. F. G., Landolfo, M., Ventura, F., & Borghi, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1604687 · Cited by 26
“More recently the results of the HPS2-THRIVE [107] and the AIMHIGH [108] studies carried out on a larger sample size of high-risk patients, did not demonstrate any significant effect of different formulations of niacin (± statins) in the prevention of major CV event with an increased risk of hemorrhagic stroke.”
ResultJosefs, T., Wouters, K., Tietge, U. J. F., Annema, W., Dullaart, R. P. F., Vaisar, T., Arts, I. C. W., Kallen, C., Stehouwer, C. D. A., Schalkwijk, C. G., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.10.012 · Cited by 26
The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01343-7 · Cited by 24
Koohi, F., Khalili, D., Mansournia, M. A., Hadaegh, F., & Soori, H. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02966-4 · Cited by 27
High-Density Lipoproteins in Kidney Disease
Kon, V., Yang, H., Smith, L. E., Vickers, K. C., & Linton, M. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158201 · Cited by 28
“The failure of clinical trials of HDL-C raising drugs, including niacin [3,4] and CETP inhibitors [5,6], has raised doubts about the potential of therapeutics designed to raise HDL-C as an approach to preventing cardiovascular events.”
BackgroundNew algorithms for treating homozygous familial hypercholesterolemia
Tromp, T. R., & Cuchel, M. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000853 · Cited by 26
Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia
Cheung, B., Sikand, G., Dineen, E. H., Malik, S., & El-Farra, A. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103414 · Cited by 30
“The HPS2-THRIVE trial did show a reduction in coronary revascularization procedures [85].”
InfluentialDyslipidemia: A Narrative Review on Pharmacotherapy
de Oliveira, L. D., de Assis, A. C. R., Giraldez, V. Z. R., Scudeler, T. L., & Soares, P. R. (2024) · Pharmaceuticals · doi:10.3390/ph17030289 · Cited by 30
Long-term follow-up of lipid-lowering trials
Packard, C. J., & Ford, I. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000230 · Cited by 26
Familial Hypercholesterolemia: Advances in Recognition and Therapy
Cartier, J. L., & Goldberg, A. C. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.07.006 · Cited by 29
Vitamin supplements in type 2 diabetes mellitus management: A review
Yan, M. K., & Khalil, H. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.04.009 · Cited by 26
“trial [41] Randomised, doubleblind, multicentre”
Pitavastatin and HDL: Effects on plasma levels and function(s)
Pirillo, A., & Catapano, A. L. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.001 · Cited by 26
Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes
Bahtiyar, G., Pujals-Kury, J., & Sacerdote, A. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1043-z · Cited by 24
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07310-y · Cited by 23
Finkel, J. B., & Duffy, D. (2014) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2014.10.015 · Cited by 29
“The recent studies evaluating niacin in addition to statin therapy in patients already at low LDL-C levels support these two points [18,19].”
BackgroundLi, J., Dreyer, R. P., Li, X., Du, X. Y., Downing, N. S., Li, L., Zhang, H., Feng, F., Guan, W., Xu, X. J., et al. (2015) · Chinese Medical Journal · doi:10.4103/0366-6999.172596 · Cited by 24
Khoury, P. E., Waldmann, E., Huby, T., Gall, J., Couvert, P., Lacorte, J., Chapman, J., Frisdal, É., Lesnik, P., Parhofer, K. G., et al. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306834 · Cited by 24
“a background of statin therapy to reduce cardiovascular outcomes.(5,42) However, both trials involved patients who reached”
BackgroundKypreos, K. E., Bitzur, R., Karavia, E. A., Xepapadaki, E., Panayiotakopoulos, G. D., & Constantinou, C. (2018) · Angiology · doi:10.1177/0003319718779533 · Cited by 29
Amaya-Montoya, M., Pinzón-Cortés, J. A., Silva-Bermúdez, L. S., Manco, D. R., Pérez-Matos, M. C., Jiménez-Mora, M. A., & Mendivil, C. O. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01291-x · Cited by 25
Shao, Q., Ma, X., Yang, Z., Li, Q.-X., Wang, Y., Liang, J., Shen, H., Liu, X., Zhou, Y., Shi, D., et al. (2022) · PubMed Central · doi:10.11909/j.issn.1671-5411.2022.06.001 · Cited by 29
Miller, M. J., Tokgözoğlu, L. S., Parhofer, K. G., Handelsman, Y., Leiter, L. A., Landmesser, U., Brinton, E. A., & Catapano, A. L. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2103541 · Cited by 26
Liu, H., Jiang, Z.-H., Yang, Z.-B., & Quan, X. (2022) · Medicine · doi:10.1097/md.0000000000030109 · Cited by 27
“Among patients with atherosclerotic vascular disease, niacin (added to statin therapy) failed to reduce cardiovascular risk despite a significant increase in HDL-C levels.[35] HDL-C is well-known as an antiinflammatory indicator which protects endothelial cells by attenuating inflammation.”
BackgroundChiesa, G., Zenti, M. G., Baragetti, A., Barbagallo, C. M., Borghi, C., Colivicchi, F., Maggioni, A. P., Noto, D., Pirro, M., Rivellese, A. A., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.019 · Cited by 27
Niacin Alternatives for Dyslipidemia: Fool’s Gold or Gold Mine? Part II: Novel Niacin Mimetics
Goel, H., & Dunbar, R. L. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0570-9 · Cited by 25
Treatment of Hypertriglyceridemia: a Review of Current Options
Vrablík, M., & Češka, R. (2015) · Physiological Research · doi:10.33549/physiolres.933199 · Cited by 26
Kroon, T., Baccega, T., Olsén, A., Gabrielsson, J., & Oakes, N. D. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m068395 · Cited by 27
Ma, Y.-B., Chan, P., Zhang, Y., Tomlinson, B., & Liu, Z. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1594776 · Cited by 23
Zvintzou, E., Xepapadaki, E., Kalogeropoulou, C. P., Filou, S., & Kypreos, K. E. (2019) · Journal of Biomedical Research · doi:10.7555/jbr.33.20190048 · Cited by 26
Frikke‐Schmidt, R. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.005 · Cited by 23
Alsayed, N., Almahmeed, W. A., Alnouri, F., Al-Waili, K., Sabbour, H. M., Sulaiman, K., Zubaid, M., Ray, K. K., & Al‐Rasadi, K. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.11.022 · Cited by 25
PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a)
Ferdinand, K. C., & Nasser, S. A. (2015) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-015-6588-3 · Cited by 24
“Nevertheless, results of the HPS2-THRIVE study did not demonstrate this long-utilized agent to be of additional benefit for CVD outcomes [79].”
ResultThe role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications
Feig, J. E., Feig, J. L., & Dangas, G. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000408 · Cited by 28
Lipid-lowering efficacy of obicetrapib: A comprehensive systematic review and meta-analysis
Masson, W., Barbagelata, L., Lobo, M., Nogueira, J. P., & Handelsman, Y. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.12.016 · Cited by 23
Capodanno, D., Mehran, R., Gibson, C. M., & Angiolillo, D. J. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1543399 · Cited by 21
Activation of HCAR2 by Niacin: Benefits Beyond Lipid Lowering
Tuteja, S. (2019) · Pharmacogenomics · doi:10.2217/pgs-2019-0092 · Cited by 22
Diabetogenic effects of cardioprotective drugs
Bell, D. S. H., & Gonçalves, E. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14295 · Cited by 23
High density lipoprotein in atherosclerosis and coronary heart disease: Where do we stand today?
Zvintzou, E., Karampela, D. S., Vakka, A., Xepapadaki, E., Karavia, E. A., Hatziri, A., Giannopoulou, P. C., & Kypreos, K. E. (2021) · Vascular Pharmacology · doi:10.1016/j.vph.2021.106928 · Cited by 27
Pividori, M., Lu, S., Li, B., Su, C., Johnson, M. E., Wei, W., Feng, Q., Namjou, B., Kiryluk, K., Kullo, I. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41057-4 · Cited by 29
Dubé, M. P., Komarow, L., Fichtenbaum, C. J., Cadden, J. J., Overton, E. T., Hodis, H. N., Currier, J. S., & Stein, J. H. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ385 · Cited by 23
“Trials of fenofibrate [10, 11] and niacin [12, 13] among non-HIV-infected participants with well-controlled LDL-C on statins have not demonstrated a benefit on CVD events, and genetic studies have questioned the relationship between HDL-C and CVD risk [14–16].”
BackgroundDyslipidemias and Cardiovascular Prevention: Tailoring Treatment According to Lipid Phenotype
Sanin, V., Pfetsch, V., & Köenig, W. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0869-3 · Cited by 31
Schooling, C. M., Huang, J. V., Zhao, J. V., Kwok, M. K., Yeung, S. L. A., & Lin, S. L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.015 · Cited by 23
“Genes related to less successful lipid modulators, such as niacin (HCAR2/3) (Landray et al., 2014), fibrates (PPARA) (Warren et al., 2016), and CETP-inhibitors (CETP) (Eyvazian and Frishman, 2017)were not significantly associatedwith IHD.”
BackgroundWarraich, H. J., & Rana, J. S. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1068-6 · Cited by 24
Wang, J., Shi, L., Zou, Y., Tang, J., Cai, J., Wei, Y., Qin, J., & Zhang, Z. (2018) · Aging · doi:10.18632/aging.101663 · Cited by 24
Samadi, S., Mehramiz, M., Kelesidis, T., Ghayour‐Mobarhan, M., Sahebkar, A. H., Esmaily, H., Moohebati, M., Farjami, Z., Ferns, G. A., Mohammadpour, A. H., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28276 · Cited by 21
Toth, P. P., Philip, S., HULL, M. L., & Granowitz, C. B. (2019) · Cardiorenal Medicine · doi:10.1159/000502511 · Cited by 22
Boden, W. E., Baum, S. J., Toth, P. P., Fazio, S., & Bhatt, D. L. (2020) · Future Cardiology · doi:10.2217/fca-2020-0106 · Cited by 25
Curran, C. S., & Kopp, J. B. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04584-8 · Cited by 22
“However, the varied responses in patients [37, 38] and in dissolution profiles of commercially available niacin formulations [36], indicate that further study of the molecules function in human health is warranted.”
BackgroundManagement of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.012 · Cited by 24
Current status of lipid management in acute coronary syndrome
Fujisue, K., & Tsujita, K. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.02.004 · Cited by 25
“However, two large trials concluded that the benefit of niacin combined with statins was not observed [23,24].”
BackgroundThe Role of Metabolite-Sensing G Protein-Coupled Receptors in Inflammation and Metabolic Disease
Recio, C., Lucy, D., Iveson, P., Iqbal, A. J., Valaris, S., Wynne, G. M., Russell, A. J., Choudhury, R. P., O’Callaghan, C. A., Monaco, C., et al. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7168 · Cited by 25
“The clear result from 25,673 vascular disease patients enrolled in the HPS study was that adding extended-release form of niacin and laropiprant to standard statin therapy did not significantly reduce cardiovascular disease events but did increase the risk of serious adverse drug effects (78).”
Škrha, J. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00905-8 · Cited by 30
Umbrella Review on Non-Statin Lipid-Lowering Therapy
Beshir, S. A., Hussain, N., Elnour, A. A., & Said, A. S. A. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211002943 · Cited by 23
Sphingolipids in HDL – Potential markers for adaptation to pregnancy?
Patanapirunhakit, P., Karlsson, H., Mulder, M. T., Ljunggren, S., Graham, D., & Freeman, D. J. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.158955 · Cited by 22
“Unfortunately, clinical trials of HDL cholesterol-raising medication repeatedly failed to reduce the risk of atherosclerotic incidence despite elevations in HDL cholesterol concentration [1 – 3].”
BackgroundAdam, S., Ho, J. H., Liu, Y., Siahmansur, T. J., Siddals, K. W., Iqbal, Z., Azmi, S., Senapati, S., New, J. P., Jeziorska, M., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac244 · Cited by 22
Korjian, S., Kazmi, S. H. A., Chi, G., Kalaycı, A., Lee, J., Talib, U., Wright, S. D., Duffy, D., Kingwell, B. A., Mehran, R., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad014 · Cited by 24
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Koschinsky, M. L., Stroes, E. S. G., & Kronenberg, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106843 · Cited by 25
Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
Brinton, E. A. (2015) · Cardiology Clinics · doi:10.1016/j.ccl.2015.02.007 · Cited by 23
Schroeder, L. L., Tang, X., Wasko, M. C., & Bili, A. (2014) · Rheumatology International · doi:10.1007/s00296-014-3194-9 · Cited by 21
Dyslipidemia in Special Ethnic Populations
Pu, J., Romanelli, R. J., Zhao, B., Azar, K. M. J., Hastings, K. G., Nimbal, V. C., Fortmann, S. P., & Palaniappan, L. P. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.013 · Cited by 20
Spotlight on HDL biology: new insights in metabolism, function, and translation
Rader, D. J. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu164 · Cited by 21
New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk
Graham, I. M., Shear, C. L., de Graeff, P., Boulton, C., Catapano, A. L., Stough, W. G., Carlsson, S. C., Backer, G. D., Emmerich, J., Greenfeder, S. A., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx031 · Cited by 22
Towards more specific treatment for diabetic dyslipidemia
Rodriguez, V., Newman, J. D., & Schwartzbard, A. Z. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000528 · Cited by 23
Lipoprotein(a): Expanding our knowledge of aortic valve narrowing
Youssef, A., Clark, J. R., Koschinsky, M. L., & Boffa, M. B. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.06.001 · Cited by 23
The mystery of evacetrapib - why are CETP inhibitors failing?
Nicholls, S. J., & Bubb, K. J. (2020) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2020.1745633 · Cited by 21
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2022) · Clinical Drug Investigation · doi:10.1007/s40261-022-01173-3 · Cited by 20
“Nicotinic acid in combination with laropiprant was excluded based on a negative EMA recommendation after the results of the HPS2-THRIVE study in 2013 [9].”
MethodZhang, X., & van der Vorst, E. P. C. (2024) · Cells · doi:10.3390/cells13131113 · Cited by 28
Lui, D. T. W., Li, L., Liu, X., Xiong, X., Tang, E. H. M., Lee, C., Woo, Y. C., Lang, B. H., Wong, C. K. H., & Tan, K. C. B. (2024) · BMC Medicine · doi:10.1186/s12916-024-03810-4 · Cited by 26
“In line with these, previous clinical trials of therapies which substantially elevate HDL-C levels did not result in lower risks of cardiovascular events [6, 29, 30].”
Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure
Katzmann, J. L., Mason, A. M., März, W., Kleber, M. E., Niessner, A., Blüher, M., Speer, T., & Laufs, U. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2153 · Cited by 25
Gibson, C. M., Kazmi, S. H. A., Korjian, S., Chi, G., Phillips, A. T., Montazerin, S. M., Duffy, D., Zheng, B., Heise, M. A., Liss, C. L., et al. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221121507 · Cited by 21
High-density lipoprotein regulates angiogenesis by long non-coding RNA HDRACA
Mo, Z.-W., Peng, Y.-M., Zhang, Y., Yan, L., Kang, B.-A., Chen, Y.-T., Li, L., Sorci‐Thomas, M. G., Lin, Y., Cao, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01558-6 · Cited by 24
“However, clinical trials have demonstrated that elevated plasma HDL levels, using cholesteryl ester transfer protein inhibitors or niacin, fail to reduce cardiovascular events.(7,8) The components of HDL are altered or modified in CAD, and HDL is no longer protective or even damages the vessels.”
BackgroundHDL functionality and crystal-based sterile inflammation in atherosclerosis
Eren, E., Ellidağ, H. Y., Aydın, Ö., & Yılmaz, N. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.09.024 · Cited by 20
Kächele, M., Hennige, A. M., Machann, J., Hieronimus, A., Lamprinou, A., Machicao, F. E., Schick, F., Fritsche, A., Stefan, N., Nürnberg, B., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144494 · Cited by 21
Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status
Sahebkar, A., Hernández‐Aguilera, A., Abelló, D., Sancho, E., Camps, J., & Joven, J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.002 · Cited by 20
“The HDL-C-raising treatment as a strategy to reduce CV events is currently under considerable debate [76–80].”
BackgroundMethodSun, W., Zhai, M., Li, D., Zhou, Y., Chen, N., Guo, M., & Zhou, S. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.07.016 · Cited by 21
Omega-3 Fatty Acid Therapy: The Tide Turns for a Fish Story
O’Keefe, J. H., Jacob, D., & Lavie, C. J. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.11.008 · Cited by 24
Assessing Cardiovascular Risk and Testing in Type 2 Diabetes
Saeed, A., & Ballantyne, C. M. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0831-4 · Cited by 23
Generoso, G., Benseñor, I. M., Santos, R. D., Santos, I. S., Goulart, A. C., Jones, S. R., Kulkarni, K. R., Blaha, M. J., Toth, P. P., Lotufo, P. A., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.05.003 · Cited by 21
Zhou, L., Liu, X., Wang, Z.-Q., Li, Y., Shi, M., Xu, Z., Ou, Z., Li, H.-M., Cheng, T.-P., Jian, Y., et al. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000611 · Cited by 19
Current Treatment of Familial Hypercholesterolaemia
Lambert, C. T., Sandesara, P. B., Isiadinso, I., Góngora, M. C., Eapen, D. J., Bhatia, N. K., Baer, J., & Sperling, L. S. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.76 · Cited by 24
Offer, A., Arnold, M., Clarke, R., Bennett, D., Bowman, L., Bulbulia, R., Haynes, R., Li, J., Hopewell, J. C., Landray, M., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.0223 · Cited by 20
Metadata
- Authors
- The HPS2-THRIVE Collaborative Group
- Corresponding author
- The HPS2-THRIVE Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 203-212
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1856460279
- Cited by
- 1,668
- References
- 33
- Citations by year
- 2026: 72 · 2025: 73 · 2024: 107 · 2023: 113 · 2022: 115 · 2021: 119 · 2020: 132 · 2019: 144 · 2018: 149 · 2017: 159 · 2016: 203 · 2015: 204 · 2014: 71
- FWCI
- 210.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
- Funders
- Harbin Medical University
- Second Affiliated Hospital of Harbin Medical University
- Cancer Research UK
- National Institute for Health and Care Research (CDF-2013-06-012)
- British Heart Foundation (RE/08/004)
- Tongji University
- Zhengzhou University
- Qingdao University
- First Affiliated Hospital of Zhengzhou University
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- extended-release niacin, laropiprant, LDL cholesterol lowering, HDL cholesterol, major vascular events, secondary prevention, vascular disease, statin therapy, diabetes management, adverse events, cardiovascular risk reduction, lipid-lowering therapy, coronary artery disease, stroke, myocardial infarction, arterial revascularization, infection risk
- MeSH terms
- Aged, Hypolipidemic Agents, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Hemorrhage, Humans, Hypercholesterolemia, Indoles, Infections, Cholesterol, LDL, Male, Middle Aged, Musculoskeletal Diseases, Niacin, Risk Factors, Treatment Failure, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.